Jeremy R. Graff, President and Chief Development Officer of Allarity Therapeutics, Inc., has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per Form 3 requirements. The document, dated 09/30/2024, indicates that Graff does not beneficially own any securities in the company. The filing was made in accordance with Section 16(a) of the Securities Exchange Act of 1934 and is a standard procedure for individuals in Graff's position, providing transparency about the holdings of company insiders. The form was filed by Graff as a single reporting person and was signed on 10/01/2024.

Jeremy R. Graff, President and Chief Development Officer of Allarity Therapeutics, Inc., has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per Form 3 requirements. The document, dated 09/30/2024, indicates that Graff does not beneficially own any securities in the company. The filing was made in accordance with Section 16(a) of the Securities Exchange Act of 1934 and is a standard procedure for individuals in Graff's position, providing transparency about the holdings of company insiders. The form was filed by Graff as a single reporting person and was signed on 10/01/2024.